Literature DB >> 11698024

Pathobiology of neuropathic pain.

M Zimmermann1.   

Abstract

This review deals with physiological and biological mechanisms of neuropathic pain, that is, pain induced by injury or disease of the nervous system. Animal models of neuropathic pain mostly use injury to a peripheral nerve, therefore, our focus is on results from nerve injury models. To make sure that the nerve injury models are related to pain, the behavior was assessed of animals following nerve injury, i.e. partial/total nerve transection/ligation or chronic nerve constriction. The following behaviors observed in such animals are considered to indicate pain: (a) autotomy, i.e. self-attack, assessed by counting the number of wounds implied, (b) hyperalgesia, i.e. strong withdrawal responses to a moderate heat stimulus, (c) allodynia, i.e. withdrawal in response to non-noxious tactile or cold stimuli. These behavioral parameters have been exploited to study the pharmacology and modulation of neuropathic pain. Nerve fibers develop abnormal ectopic excitability at or near the site of nerve injury. The mechanisms include unusual distributions of Na(+) channels, as well as abnormal responses to endogenous pain producing substances and cytokines such as tumor necrosis factor alpha (TNF-alpha). Persistent abnormal excitability of sensory nerve endings in a neuroma is considered a mechanism of stump pain after amputation. Any local nerve injury tends to spread to distant parts of the peripheral and central nervous system. This includes erratic mechano-sensitivity along the injured nerve including the cell bodies in the dorsal root ganglion (DRG) as well as ongoing activity in the dorsal horn. The spread of pathophysiology includes upregulation of nitric oxide synthase (NOS) in axotomized neurons, deafferentation hypersensitivity of spinal neurons following afferent cell death, long-term potentiation (LTP) of spinal synaptic transmission and attenuation of central pain inhibitory mechanisms. In particular, the efficacy of opioids at the spinal level is much decreased following nerve injury. Repeated or prolonged noxious stimulation and the persistent abnormal input following nerve injury activate a number of intracellular second messenger systems, implying phosphorylation by protein kinases, particularly protein kinase C (PKC). Intracellular signal cascades result in immediate early gene (IEG) induction which is considered as the overture of a widespread change in protein synthesis, a general basis for nervous system plasticity. Although these processes of increasing nervous system excitability may be considered as a strategy to compensate functional deficits following nerve injury, its by-product is widespread nervous system sensitization resulting in pain and hyperalgesia. An important sequela of nerve injury and other nervous system diseases such as virus attack is apoptosis of neurons in the peripheral and central nervous system. Apoptosis seems to induce neuronal sensitization and loss of inhibitory systems, and these irreversible processes might be in common to nervous system damage by brain trauma or ischemia as well as neuropathic pain. The cellular pathobiology including apoptosis suggests future strategies against neuropathic pain that emphasize preventive aspects.

Entities:  

Mesh:

Year:  2001        PMID: 11698024     DOI: 10.1016/s0014-2999(01)01303-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  212 in total

1.  Effects of multiple intrathecal administration of L-arginine with different doses on formalin-induced nociceptive behavioral responses in rats.

Authors:  Kuan Li; Wen-Xiu Qi
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

Review 2.  Purinoceptors in microglia and neuropathic pain.

Authors:  Tuan Trang; Simon Beggs; Michael W Salter
Journal:  Pflugers Arch       Date:  2006-04-22       Impact factor: 3.657

3.  [Endogenous cannabinoid system. Effect on neuronal plasticity and pain memory].

Authors:  S C Azad; V Huge; P Schöps; C Hilf; A Beyer; H-U Dodt; G Rammes; W Zieglgänsberger
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

4.  Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain.

Authors:  Alexia E Metz; Hau-Jie Yau; Maria Virginia Centeno; A Vania Apkarian; Marco Martina
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

5.  CX3CR1 Mediates Nicotine Withdrawal-Induced Hyperalgesia via Microglial P38 MAPK Signaling.

Authors:  Yonghong Ding; Wenhui Shi; Guannan Xie; Ailan Yu; Qinghe Wang; Zongwang Zhang
Journal:  Neurochem Res       Date:  2015-09-19       Impact factor: 3.996

6.  Identification of MEK1 as a novel target for the treatment of neuropathic pain.

Authors:  A Ciruela; A K Dixon; S Bramwell; M I Gonzalez; R D Pinnock; K Lee
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

7.  Effects of histamine on spontaneous neuropathic pain induced by peripheral axotomy.

Authors:  Jie Yu; Guo-Dong Lou; Jia-Xing Yue; Ying-Ying Tang; Wei-Wei Hou; Wen-Ting Shou; Hiroshi Ohtsu; Shi-Hong Zhang; Zhong Chen
Journal:  Neurosci Bull       Date:  2013-03-13       Impact factor: 5.203

8.  Ranolazine attenuates behavioral signs of neuropathic pain.

Authors:  Harry J Gould; Colleen Garrett; Renee R Donahue; Dennis Paul; Ivan Diamond; Bradley K Taylor
Journal:  Behav Pharmacol       Date:  2009-12       Impact factor: 2.293

9.  Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats.

Authors:  Erin D Milligan; Carin Twining; Marucia Chacur; Joseph Biedenkapp; Kevin O'Connor; Stephen Poole; Kevin Tracey; David Martin; Steven F Maier; Linda R Watkins
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 10.  Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain.

Authors:  Paola Sacerdote; Silvia Franchi; Sarah Moretti; Mara Castelli; Patrizia Procacci; Valerio Magnaghi; Alberto E Panerai
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.